Circular Genomics Raises $15M to Advance Circular RNA Platform for Alzheimer’s Detection
The financing will accelerate clinical validation and commercial readiness of brain-derived blood biomarkers based on circular RNA technology.
The financing will accelerate clinical validation and commercial readiness of brain-derived blood biomarkers based on circular RNA technology.
The system combines enhanced sensitivity with automation to detect M-proteins at low concentrations, supporting early diagnosis of plasma cell disorders.
The all-in-one diagnostic platform combines hematology, biochemistry, and immunoassay testing in a single run.
The automated workflow on SPT's firefly platform aims to reduce manual pipetting by up to 80% and improve consistency for large-scale transcriptomic studies.
The collaboration aims to make home-based Alzheimer's biomarker testing more accessible through virtually painless blood collection technology.